Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

MLA

Fiona Day, et al. “Chemoradiotherapy with Concurrent Durvalumab for the Palliative Treatment of Oligometastatic Oesophageal and Gastrooesophageal Carcinoma with Dysphagia: A Single Arm Phase II Clinical Trial (PALEO, Sponsored by the Australasian Gastro-Intestinal Trials Group).” BMC Cancer, vol. 22, no. 1, Dec. 2022, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-022-10407-8.

APA

Fiona Day, Swetha Sridharan, James Lynam, Craig Gedye, Catherine Johnson, Allison Fraser, Stephen R. Thompson, Michael Michael, Trevor Leong, Amitesh Roy, Mahesh Kumar, Andre van der Westhuizen, Gaik T. Quah, Hiren Mandaliya, Girish Mallesara, Joshua Sappiatzer, Christopher Oldmeadow, & Jarad Martin. (2022). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). BMC Cancer, 22(1), 1–10. https://doi.org/10.1186/s12885-022-10407-8

Chicago

Fiona Day, Swetha Sridharan, James Lynam, Craig Gedye, Catherine Johnson, Allison Fraser, Stephen R. Thompson, et al. 2022. “Chemoradiotherapy with Concurrent Durvalumab for the Palliative Treatment of Oligometastatic Oesophageal and Gastrooesophageal Carcinoma with Dysphagia: A Single Arm Phase II Clinical Trial (PALEO, Sponsored by the Australasian Gastro-Intestinal Trials Group).” BMC Cancer 22 (1): 1–10. doi:10.1186/s12885-022-10407-8.